Objective: Galanin (GAL) has a role in the regulation of food intake by way of acting on the central nervous system in rodents. High serum GAL levels have been observed in obese human subjects, suggesting that peripheral GAL has a role in the regulation of energy balance and that elevated circulating GAL levels contribute to the development of obesity and obesity-associated metabolic impairments. Currently, it is not known how chronically increased levels of circulating GAL affect energy balance. The purpose of this study is to clarify the importance of chronically increased levels of circulating GAL on energy balance in a transgenic mouse model. Research design and methods: Male wild-type and homozygous galanin transgenic (GAL-Tg) mice were used to study the peripheral effects of a 10-fold increase in circulating GAL on food intake, body weight, lipid metabolism, hepatic steatosis, glucose homeostasis and energy expenditure. Results: In the absence of an orexigenic effect, GAL-Tg mice had increased body weight, visceral adiposity, total serum cholesterol, total serum triglycerides and hyperinsulinemia, as well as impaired glucose tolerance. Compared with wild-type mice, the obese phenotype observed in the GAL-Tg mice was attributed to decreased oxygen consumption and carbon dioxide production, and this effect was independent of any changes in food intake or horizontal activity. In this obese model, GAL contributed to the development of fatty liver disease, which was associated with impaired glucose tolerance, as well as a reduction in heat production and metabolic rate. Conclusions: Chronically elevated GAL may regulate body weight, metabolic rate, and lipid and carbohydrate metabolism through a mechanism that is independent of feeding regulation. The obese phenotype in the GAL-Tg mice is related to the reduced energy expenditure and insulin resistance. These findings support the hypothesis that increased circulating GAL levels contribute to the development of metabolic syndrome.
Introduction
Galanin (GAL) is a 29-amino acid neuropeptide that is widely distributed in the central and peripheral nervous system. 1, 2 The N-terminal amino acid sequence is roughly 90% conserved among species, which indicates the importance of this molecule. 3, 4 Although GAL is expressed most abundantly in the hypothalamus, it is also synthesized and secreted from the anterior pituitary gland. 5, 6 GAL exerts its effects through the activation of GAL receptors (GalR1, GalR2 and GalR3), which are widely distributed in the mammalian central and peripheral nervous systems. 7, 8 It is well documented that GAL has a critical role in the regulation of energy homeostasis. Many studies have confirmed that direct administration of GAL to the central nervous system stimulates feeding in rodents. 9 Increased GAL signaling in the central nervous system, specifically at the paraventricular nucleus, stimulates feeding in a dosedependent manner. 10 The stimulation of feeding occurs after a single injection of GAL into the paraventricular nucleus, and is strongest during the early dark period of the lightdark cycle. The GAL-induced stimulation of feeding is associated with a short-term reduction of the metabolic rate. 11 It is hypothesized that GAL elicits its orexigenic effects partly through activating the mesolimbic dopaminergic system, which increases the production of extracellular dopamine. 12 GAL is reported to increase the preference for a high-fat diet, 13 although other studies have not observed any differences in macronutrient choice. 9, 14 In contrast with other orexigenic peptides, such as neuropeptide Y, chronic intracerebroventricular administration of GAL does not induce sustained obesity. 15 Although elevated serum levels of GAL are associated with obesity in humans, the role of peripheral GAL in the regulation of energy balance is not well defined. [16] [17] [18] The stimulatory effects of GAL on the release of growth hormone and prolactin are well established in both human and rodent studies. [19] [20] [21] Initially, we generated a GAL transgenic (GAL-Tg) mouse model to further clarify the neuroendocrine effects of overexpression and oversecretion of GAL in somatotrophs, which induces the development of pituitary adenomas. 22 Surprisingly, we observed that the GAL-Tg mice developed an obese phenotype. The objective of this study is to clarify GAL-mediated control of body weight and lipid metabolism using the GAL-Tg model. Although most experiments that study the involvement of GAL in energy balance focus on its central nervous system administration, our model of chronically elevated levels of circulating GAL may elucidate the importance of the peripheral versus the central effects of GAL on energy balance and obesity.
Research design and methods

Animals
The GAL-Tg mice on a C57BL/6J Â SJL background were generated earlier. 22 Male homozygous offspring from the colony were backcrossed for at least six generations into the C57BL/6J background. Wild-type animals of the same genetic background, gender and age were used as controls. The mice were housed under a 12 h light-dark cycle with ad libitum access to water and laboratory chow (crude protein 22%, fat 5%, fiber 5%, ash 6% and added mineral 2.5%). All procedures were in accordance with the Animal Protocol Review Board of the University of Manitoba. All animals were ear tagged upon weaning.
Experiment 1: Effect of galanin overproduction on body weight and lipid metabolism The body weight of 10 male wild-type and 15 male homozygous GAL-Tg mice, born at the same time, was measured monthly up to 9 months of age. At 9 months of age, the animals were anesthetized with isofluorane and killed during the early light phase after an overnight fast. Physical parameters such as body weight, length and waist circumference were measured. Blood was also collected by cardiac puncture at the time of killing. Liver and epididymal fat were dissected and weighted. Blood was allowed to clot on ice, and serum was obtained by centrifugation at 11 000 r.p.m. for 10 min. Serum cholesterol, triglyceride, insulin and GAL levels were measured.
Experiment 2: Energy expenditure, food intake and glucose tolerance test To further identify possible mechanisms by which GAL overproduction induces obesity, 4 month-old male wild-type (n ¼ 5) and GAL-Tg (n ¼ 5) mice were used. Animals were housed in individual cages. The mice were acclimated to handling for 4 days, and body weight and food intake were measured daily for 10 days. The metabolic rates and activity levels were determined using indirect calorimetry (Accuscan, Columbus, OH, USA) as described earlier. 23 Mice were acclimated to the metabolic cage system by placing animals in the cages for 24 h before starting data collection. Oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), heat production and spontaneous physical activity (horizontal activity) were measured every 5 min for 23 h (1500-1400 h) under ambient temperature and ad libitum fed conditions. Averages of each variable were calculated for the light phase (day, 0600-1800 h), dark phase (night, 1800-0600 h) and the entire 23-h period and these were used for the statistical analysis. Glucose tolerance tests were performed on the same wild-type (n ¼ 5) and GAL-Tg mice (n ¼ 5) a week later. Mice were fasted overnight for 14 h, and were injected intraperitoneally with glucose (2 mg g -1 body weight) at 1000 h. Blood was collected from the tail vein at 0, 30, 60, 120 and 180 min after injection. Blood glucose was measured using a glucose meter (Glucometer Elite, Bayer Healthcare LLC7151, Berkeley, CA, USA).
Serum analysis
Serum lipids (total cholesterol and triglycerides) were measured using colorimetric assay kits (Sigma Diagnostics, St Louis, MO, USA) according to the manufacturer's instructions. Control serum Cardiolipid Level 1 (C 4571; Sigma, St Louis, MO, USA) was used as an internal quality control for both the triglyceride and total cholesterol assays. Total serum cholesterol was measured using the Infinity Cholesterol Reagent # 401 (Sigma Diagnostics) and the cholesterol calibrator (C 0284; Sigma). The intra-assay co-efficiency of variation was 8.4%, and all samples were tested in the same analytical run. Total serum triglycerides were measured using the Infinity Triglycerides Reagent # 344 (Sigma Diagnostics) and the triglyceride calibrator G1394 (Sigma). All samples were tested in the same analytical run and the intra-assay co-efficiency of variation was 3.4%. Insulin levels were determined by using a sensitive rat insulin radioimmunoassay kit (Linco, St Charles, MO, USA), which has 100% sensitivity to mouse insulin. The sensitivity of the assay was 0.02 ng ml -1 . The intra-assay co-efficiency of variation was 6.7%. GAL levels were determined using a radioimmunoassay kit from Bachem as described earlier. 24 Galanin and metabolic syndrome NJ Poritsanos et al
Liver histology
The liver was excised and immediately frozen on dry ice. Frozen fresh and formalin-fixed liver tissues were sectioned and stained with Oil-Red-O and hematoxylin to visualize neutral lipids and the morphological architecture of the tissue. In brief, cryosections of 10 mm were air dried and fixed in formalin, rinsed with water followed with a 60% isopropanol rinse. The sections were stained with freshly prepared 0.5% Oil-Red-O solution, rinsed with 60% isopropanol and lightly stained with hematoxylin.
Statistical analysis
Statistical analysis was performed by using the JMP statistical software (SAS Institute Inc, Cary, NC, USA). Comparison between two groups was performed by using the Student's ttest. A P-value o 0.05 was considered significant. All results are expressed as the means ± s.e.m.
Results
Experiment 1: Effect of the GAL-Tg on body weight, adiposity and lipid metabolism
The body weight of the GAL-Tg mice and the age-matched wild-type control mice were monitored over a 9-month period. We have used only male mice to avoid the implications of fluctuating steroid levels in female mice. From 2 months of age, the body weight of the GAL-Tg mice increased by 14.9%, when compared with the wild-type control littermates (Figure 1a ). The GAL-Tg mice showed an even greater sensitivity to increased body weight over time. At 9 months of age, the body weight of the male GAL-Tg mice exceeded that of the wild-type control mice by 35.6% (Po0.001) (Figure 1a ). Epididymal fat pad weight of the GAL-Tg mice was significantly higher (Po0.01) when compared with the wild-type control mice (Figures 1b and c) .
Moreover, compared with the wild-type control mice, the male GAL-Tg mice had significantly elevated levels of total serum cholesterol (Po0.01) ( Figure 1d ) and triglycerides (Po0.05) (Figure 1e ). The GAL-Tg mice had increased levels of both fasting and non-fasting serum insulin (Po0.05) (Figure 1f ). The increase in fasted insulin levels positively correlated with the significant increase in the epididymal fat pads (r 2 ¼ 0.936; Po0.01). As expected, serum GAL levels were significantly higher in the GAL-Tg mice (Po0.001) (Figure 1g ).
Experiment 2: Effect of the GAL-Tg on food intake and energy expenditure
To analyze whether the obese phenotype observed in the GAL-Tg mice is due to increased food intake or reduced energy expenditure, 4-month-old mice were studied using indirect calorimetry. Consistent with the results described in experiment 1, body weight was significantly increased in the GAL-Tg mice as compared with the wild-type control mice (Po0.01) (Figure 2a ). Despite increased body weight, the daily food intake of the GAL-Tg mice did not differ from the wild-type control mice (P ¼ 0.17) (Figure 2b ). The GAL-Tg mice showed a significant decrease in VO 2 (23 h, Po0.05; day, Po0.01; night, Po0.05) (Figure 2c ) and VCO 2 (day, Po0.05) (Figure 2d ). Whole-body heat production did not differ between the two genotypes (data not shown). When heat production was normalized to body weight, heat production in the GAL-Tg mice was significantly reduced when compared with the wild-type control mice (23 h, Po0.05; day, Po0.01; night, Po0.05) (Figure 2e ). Over-expression of GAL had no effect on general activity levels as measured by horizontal activity (Figure 2f) .
Effect of the GAL-Tg on glucose homeostasis
After an overnight fast, there was no difference in blood glucose levels between wild type and GAL-Tg mice ( Figure 3 ). During the glucose tolerance test, the glucose clearance rate between 30 and 120 min post-glucose intraperitoneal injection was significantly lower in the GAL-Tg mice as compared with the wild-type control mice (Po0.05) (Figure 3) .
Effect of the GAL-Tg on body composition
The body composition data show that besides the significant increase in body weight (Po0.01) (Figure 2a ), the weight of the visceral fat pad and the liver are also increased (Po0.01 and Po0.05, respectively) ( Table 1) . Normalization of visceral fat pad weight to total body weight shows a statistically significant difference between the two genotypes (Po0.01) ( Table 1) . Although the liver weight is increased in the GAL-Tg mice, normalization of liver weight to total body weight does not reach statistical significance. Waist circumference is also significantly increased in the GAL-Tg mice (Po0.01) ( Table 1 ). The length of the GAL-Tg mice is increased, which is explained by the concurrent oversecretion of growth hormone in our GAL-Tg model (Po0.01) ( Table 1) .
Effect of the GAL-Tg on hepatic lipid metabolism Macroscopically, the livers of the GAL-Tg mice were enlarged and paler in color due to excessive accumulation of fat. Microscopically, the livers of the GAL-Tg mice showed steatosis ( Figure 4) . Fatty liver was shown by increased lipid droplet accumulation in hepatocyte vacuoles that compressed and displaced the nucleus to the periphery (typical of hepatocyte ballooning). Furthermore, initial stages of architectural remodeling of the liver were observed.
Discussion
GAL has a role in the regulation of energy balance through its actions in the central nervous system. 9, 25 In contrast to
Galanin and metabolic syndrome NJ Poritsanos et al the role of GAL in the central nervous system, the role of peripheral GAL in the regulation of energy balance is not well understood. Circulating levels of GAL are elevated in obese individuals relative to lean individuals, suggesting that elevated peripheral GAL may contribute to the development of obesity and obesity-associated impairments. [16] [17] [18] To verify this possibility, we characterized the metabolic phenotype of transgenic mice (GAL-Tg mice). We have observed that these mice develop an obese phenotype from at least the age of 8 weeks. 22 This model of GAL-Tg mice is unique compared Wild Type GAL-Tg Figure 1 The effect of galanin (GAL) overexpression on metabolism. Body weight (a), epididymal fat pad weight (b, c), serum levels of total cholesterol (d),
triglyceride (e), insulin (f) and GAL (g) were measured in 9-month-old male wild-type and galanin transgenic (GAL-Tg) mice. Data are expressed as mean ± s.e.m.
(n ¼ 10-15 per group). *Po0.05, **Po0.01 and ***Po0.001 by Student's t-test.
Galanin and metabolic syndrome NJ Poritsanos et al with other GAL-Tg models [26] [27] [28] in that GAL is oversecreted in the circulation with serum GAL levels 10-fold higher than wild-type mice. This feature makes these mice an excellent model to study the functional significance of GAL. This study shows that GAL-Tg mice develop obesity, hypometabolism and abnormal lipid and carbohydrate metabolism. Although centrally administered GAL acutely increases food intake and reduces energy expenditure, repeated longterm central administration of GAL does not increase food intake and body weight. 15 In addition, transgenic mice selectively overexpressing GAL in catecholaminergic neurons do not have significant differences in food intake or body weight when compared with wild-type controls. 26 In contrast to the orexigenic effect of central GAL, intraperitoneal injections of GAL do not affect food intake. 9, 10 Furthermore, peripheral administration of galnon, a systematically acting subtype non-selective GAL receptor agonist, suppressed feeding, pointing to the possible importance of peripheral targets. 29 Consistent with these pharmacological studies, our GAL-Tg mice were not hyperphagic. However, in the absence of hyperphagia and contrary to the prediction that was based on earlier studies, the GAL-Tg mice developed obesity. Elevated peripheral GAL levels reduce hypothalamic GAL expression. 30 Therefore, we cannot rule out the Horizontal Activity (counts/hr) Figure 2 The effect of galanin (GAL) overexpression on body weight, food intake and energy expenditure. Metabolic cage studies were performed using 4-monthold wild-type and galanin transgenic (GAL-Tg) mice. Body weight (a) was measured at the beginning of the metabolic cage study. Daily food intake was measured for 10 days before the metabolic cage study and average daily food intake (b) was calculated. Mice were placed in the metabolic cage and O 2 consumption (c), CO 2 production (d), heat production (e) and horizontal activity (f) were continuously measured for 2 days. The data during the last 23 h were used for the statistical analysis. Data are expressed as mean ± s.e.m. (n ¼ 5 per group). *Po0.05 and **Po0.01 by Student's t-test.
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As we mentioned earlier the stimulatory effects of GAL on the release of growth hormone and prolactin are well established in both human and rodent studies. [19] [20] [21] Similarly, our GAL-Tg mice have increased secretion of prolactin and to a lesser extent growth hormone as well. 22 Thus, it could be argued that the observed obese phenotype in our GAL-Tg mice is due to these neuroendocrine alterations. Although several transgenic animal models of overexpression of GAL, growth hormone, prolactin or a combination of them have been described, none of them has shown the obesity phenotype that we describe here. 24, [26] [27] [28] 30, [31] [32] [33] [34] Furthermore, a GAL-Tg mouse very similar to our GAL-Tg has been described, with targeted overexpression of GAL in lactotrophs and development of pituitary tumors, but without increased serum GAL levels. 27 No obese phenotype has been observed in this model either. As the only unique attribute in our GAL-Tg mice compared with all the other mice is the elevated circulating GAL levels in the serum, we believe that the increased adiposity in the GAL-Tg mice is related to increased serum GAL levels rather than GAL-Tg-induced neuroendocrine alterations. The possibility that endogenous GAL may have a physiological role in body weight regulation, as well as contribution to the development of obesity, is supported by reports regarding elevated hypothalamic GAL levels in rodents with genetic or dietary-induced obesity. [35] [36] [37] [38] Earlier studies have shown that knockout mice of either GAL or the GalR1 receptor do not have altered food intake or body weight when the mice were fed a regular laboratory chow. 39, 40 As these results were generated with conventional knockout mice, compensatory genetic or biochemical effects may mask the underlying phenotype of the mutation. However, GAL and GalR1 knockout mice are less sensitive to high-fat diet-induced increases in energy intake and body weight gain when compared with wild-type control mice. Wild-type and galanin transgenic (GAL-Tg) mice were fasted for 14 h and injected intraperitoneally (i.p.) with glucose (2 mg g -1 body weight). Blood glucose levels were measured up to 3 h after glucose injection. Data are expressed as mean ± s.e.m. (n ¼ 5 per group). *Po0.05 (Student's t-test). Figure 4 The effect of galanin (GAL) overexpression on hepatic steatosis.
Liver sections were prepared from 9-month-old galanin transgenic (GAL-Tg) (a) and wild-type (b) mice and stained with Oil-Red-O and hematoxylin (a, b). Scale bar ¼ 100 mm; magnification, Â 40.
The obese phenotype, which occurs without increased food intake in our transgenic model, led us to speculate that the increased body weight, adiposity and development of hypercholesteremia are related to defects in energy expenditure. The GAL-Tg mice have reduced oxygen consumption and carbon dioxide production, which are indicative of decreased energy expenditure. Heat production was also decreased in the GAL-Tg mice, as compared with wild-type control mice. In our study, there was no significant difference in activity levels between the GAL-Tg and wildtype control mice. These findings indicate that GAL suppresses energy expenditure and thermogenesis independent of physical activity levels. Consistent with our findings, it has been reported that direct injection of GAL into the hypothalamic paraventricular nucleus produced a shortterm inhibitory effect on energy expenditure without reducing locomotor activity. 11 It has also been suggested that inhibition of thermogenesis and reduced energy expenditure is mediated through the b-adrenergic receptors of the noradrenergic system in peripheral tissues. As reported earlier, centrally administered GAL reduces the firing rate of the sympathetic nerves, which innervate brown adipose tissue (BAT), in a dose-dependent manner. 42 Therefore, the reduced heat production in the GAL-Tg mice may be due to reduced activity of the sympathetic nervous system. It is unclear whether peripherally elevated GAL levels reduce sympathetic outflow to BAT through the central nervous system or whether GAL modulates the activity of the sympathetic nerves at the peripheral level. Intravenously infused GAL reduces plasma norepinephrine levels in human subjects, 43 further suggesting that circulating GAL acts on the autonomic nervous system at the peripheral level. The reduced energy expenditure and metabolic rate in our transgenic model indicates that GAL has an effect on fat storage. The increased body weight in our model is mainly attributed to an increase in epididymal fat tissue, and to some extent an increase in liver weight. Increased lipid accumulation in these tissues leads to insulin resistance and metabolic impairments in triglyceride synthesis, transport and deposition.
Furthermore, increased levels of insulin with impaired glucose clearance in a glucose tolerance test (Figure 3 ) are indicative of insulin resistance. Consequently, elevated levels of insulin in the GAL-Tg mice, because of the insulin resistance in the liver, may stimulate hepatic triglyceride production and lipid synthesis by activating lipid biosynthetic enzymes fatty acid synthase, acetyl-CoA carboxylase and the transcription factor steroid regulatory elementbinding protein 1c. 44, 45 Preliminary results indicate increased hepatic mRNA levels of the insulin responsive lipogenic transcription factor steroid regulatory elementbinding protein 1c in the GAL-Tg mice (our unpublished observation). Similarly, the incidence of fatty liver in our GAL-Tg model is in accordance with the suggested impairment in lipid metabolism. 45 Several recent studies, similarly to our observation, have shown a positive correlation between plasma triglycerides and GAL. 37, 38, [46] [47] [48] [49] Intrahypothalamic GAL administration promoted partitioning of lipids away from oxidation in muscle toward storage in adipose tissue. These effects were accompanied by elevated levels of triglycerides, non esterified fatty acid (NEFA) and lipoprotein lipase activity in adipose tissue. 38 Furthermore, clinical studies have suggested that variation in the GAL promoter region influences triglyceride levels in humans and that the associated variant is likely to be functional 49 In summary, we have shown that chronically elevated GAL may regulate body weight, metabolic rate, and lipid and carbohydrate metabolism through a mechanism that is independent of feeding regulation. These findings support the hypothesis that increased circulating GAL levels contribute to the development of metabolic syndrome. Overall, these findings establish an animal model to study the molecular mechanisms involved in the development of obesity, metabolic syndrome and fatty liver disease. Our findings suggest potential therapeutic actions of the GAL receptor ligands at sites relevant to fat deposition and lipid metabolism.
